Holen Sie sich die Stockscreener-App
25.39
2.21%
0.55
Handel nachbörslich:
25.35
-0.04
-0.16%
Schlusskurs vom Vortag:
$24.84
Offen:
$25.22
24-Stunden-Volumen:
1.40M
Relative Volume:
0.89
Marktkapitalisierung:
$4.35B
Einnahmen:
$1.10B
Nettoeinkommen (Verlust:
$375.65M
KGV:
11.56
EPS:
2.1963
Netto-Cashflow:
$113.59M
1W Leistung:
+1.20%
1M Leistung:
+0.28%
6M Leistung:
-3.09%
1J Leistung:
+9.20%
1-Tages-Spanne:
$24.99
$25.78
1-Wochen-Bereich:
$24.23
$25.78
52-Wochen-Spanne:
$19.69
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.39 | 4.25B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
4 Medical Stocks With the Right Setup for Q2 Earnings Beats - TradingView
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc (ACAD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACAD|ACADIA Pharmaceuticals Inc|Price:24.840|Chg%:+0.010 - TradingKey
Stifel Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Raises Target Price to $25 - Moomoo
ACAD: Acadia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia gains fast track status for remlifanserin in Alzheimer's disease psychosis - MSN
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate - TradingView
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a 30% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Mizuho reiterates Acadia stock rating on Alzheimer’s trial progress - Investing.com UK
Stifel raises Acadia Pharmaceuticals price target on drug potential By Investing.com - Investing.com South Africa
Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com
Acadia Pharmaceuticals (ACAD) Receives FDA Fast Track for Remlif - GuruFocus
Lobbying Update: $700,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - BioSpace
ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks - TradingView
JP Morgan Maintains ACADIA Pharmaceuticals (ACAD) Overweight Recommendation - MSN
ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk - webull.com
ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GAROFALO ELIZABETH A.moomoo - Moomoo
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - BioSpace
Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Press Release: Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - Moomoo
Acadia Pharmaceuticals to announce Q2 2026 results on August 4 - scanx.trade
Acadia to Host Q2 Results Call After Markets Close Aug. 4 - Stock Titan
BofA Securities Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $30 - Moomoo
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence - TradingKey
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - The Motley Fool
Acadia rises as EU backs Rett syndrome therapy - MSN
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - Moomoo
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):